Viewing Study NCT05990621



Ignite Creation Date: 2024-05-06 @ 7:23 PM
Last Modification Date: 2024-10-26 @ 3:05 PM
Study NCT ID: NCT05990621
Status: RECRUITING
Last Update Posted: 2023-08-14
First Post: 2023-08-07

Brief Title: Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms
Sponsor: Changhai Hospital
Organization: Changhai Hospital

Study Overview

Official Title: A Single-arm Open-label Dose-escalationExpansion Early-phase Clinical Study of Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urological Neoplasms
Status: RECRUITING
Status Verified Date: 2023-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a single-arm open-label exploratory clinical study to evaluate the safety tolerability and preliminary efficacy of Anti-CD70 CAR-T cell injection in patients with CD70-positive Advanced Urologic Neoplasms
Detailed Description: This study will include two parts dose escalation phase accelerated titration and 33 design followed by a dose expansion phase All eligible participants will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by CAR-T cell injection

The dose escalation phase will determine the maximum tolerated dose MTD of Anti-CD70 CAR-T cell injection Additional patients will be enrolled in the dose expansion phase to further characterize the safety profile and evaluate the efficacy of Anti-CD70 CAR-T cell injection and establish recommended phase 2 dose RP2D

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None